Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.48 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22848102 | 0.94 | SIGMAR1 (0.54) | SIGMAR1KDM4ETP53HRH3MEN1 | |
| SCHEMBL22848101 | 0.92 | SIGMAR1 (0.52) | SIGMAR1KDM4ETP53HRH3MEN1 | |
| SCHEMBL22848081 | 0.92 | SIGMAR1 (0.52) | SIGMAR1KDM4ETP53HRH3MEN1 | |
| SCHEMBL22848077 | 0.92 | SIGMAR1 (0.52) | SIGMAR1KDM4ETP53HRH3MEN1 | |
| SCHEMBL2384959 | 0.80 | KDM4E (0.80) | KDM4ETP53HRH3POLBCHRNA10 | |
| SCHEMBL5356200 | 0.80 | KDM4E (0.62) | KDM4ETP53HRH3POLBCHRNA10 | |
| SCHEMBL1815889 | 0.78 | DRD2 (0.49) | SIGMAR1KDM4EDRD2DRD3 | |
| SCHEMBL22848357 | 0.78 | DRD3 (0.49) | MEN1DRD2DRD3 | |
| SCHEMBL12082219 | 0.78 | MAPT (0.51) | MEN1DRD2DRD3HTR7 | |
| SCHEMBL27160034 | 0.78 | SLC6A2 (0.55) | DRD2DRD3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-10-06 | — | — | US | disclosed |
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-02-03 | — | — | US | disclosed |
| WO-2005007625-A2 | HETEROCYCLIC AMIDES WITH ANTI-TUBERCULOSIS ACTIVITY | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, NDUFS5 | SIGMAR1 119/4885KDM4E 2025/4885TP53 4411/4885 |
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, HDAC5 | SIGMAR1 114/4885KDM4E 1722/4885TP53 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.